Biohaven Pharmaceutical Holding Long Term Debt 2016-2022 | BHVN

Biohaven Pharmaceutical Holding long term debt from 2016 to 2022. Long term debt can be defined as the sum of all long term debt fields.
  • Biohaven Pharmaceutical Holding long term debt for the quarter ending June 30, 2022 was $0.765B, a 179.05% increase year-over-year.
  • Biohaven Pharmaceutical Holding long term debt for 2021 was $0.627B, a 134.32% increase from 2020.
  • Biohaven Pharmaceutical Holding long term debt for 2020 was $0.267B, a INF% increase from 2019.
  • Biohaven Pharmaceutical Holding long term debt for 2019 was $0B, a NAN% decline from 2018.
Biohaven Pharmaceutical Holding Annual Long Term Debt
(Millions of US $)
2021 $627
2020 $267
2019 $
2018 $
2017 $
2016 $1
2015 $
Biohaven Pharmaceutical Holding Quarterly Long Term Debt
(Millions of US $)
2022-06-30 $765
2022-03-31 $634
2021-12-31 $627
2021-09-30 $619
2021-06-30 $274
2021-03-31 $271
2020-12-31 $267
2020-09-30 $264
2020-06-30
2020-03-31
2019-12-31
2019-09-30
2019-06-30
2019-03-31
2018-12-31
2018-09-30
2018-06-30
2018-03-31
2017-12-31
2017-09-30
2017-06-30
2017-03-31 $1
2016-12-31 $1
2016-09-30
2016-06-30
2016-03-31
2015-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $10.535B $0.463B
Biohaven Pharmaceutical is a commercial-stage biotechnology company focused on developing, and commercializing products, primarily in the fields of central nervous system diseases, including neurological and rare disorders.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $160.059B 9.71
GSK (GSK) United Kingdom $81.408B 9.78
Bio-Rad Laboratories (BIO.B) United States $15.412B 34.05
QIAGEN (QGEN) Netherlands $11.018B 18.45
Ginkgo Bioworks Holdings (DNA) United States $5.561B 0.00
Arcus Biosciences (RCUS) United States $1.821B 35.53
Myovant Sciences (MYOV) United Kingdom $1.600B 0.00
Emergent Biosolutions (EBS) United States $1.482B 8.59
Zymeworks (ZYME) Canada $0.390B 0.00
Enzo Biochem (ENZ) United States $0.120B 0.00
Gelesis Holdings (GLS) United States $0.104B 0.00
SQZ Biotechnologies (SQZ) United States $0.097B 0.00
Ambrx Biopharma (AMAM) United States $0.089B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00